| Name | Title | Contact Details |
|---|
Ossio is an orthopedic medical device company founded in Israel in 2014 with the vision to completely transform the orthopedic experience for physicians, patients, and payors. Ossio`s mission is to replace metal implants as the standard of care in the $10B+ orthopedic fixation market (screws, pins, plates) with an intelligent bone regeneration technology.
Quincy Lab is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NovaSignal Corp. is a medical technology company whose mission is to save lives by unlocking the hidden power of blood flow data. The company`s FDA-cleared NovaGuide™ Intelligent Ultrasound combines non-invasive ultrasound, robotics, and artificial intelligence to assess real-time cerebral blood flow. Through the use of cloud computing and data analytics services, NovaSignal supports physicians in their clinical decision making, leading to better patient outcomes.
Headquartered in Largo, Florida, BioDerm is a leading provider of disposable medical devices and wound care supplies to patients with chronic conditions. BioDerm manufactures proprietary hydrocolloid products for urinary management, securement, infection control and skin protection, challenging accepted inferior standards of care by creating products that reduce infection rates, add comfort and reliability, and vastly improve quality of life. BioDerm`s flagship products for male urinary incontinence are Men`s Liberty for the home setting and Men`s Liberty Acute for in-patient settings. Other products include CathGrip for securement and BioPlus and FreeDerm for skin protection.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.